ibrutinib,rituximab
abbvie,janssen
[' ibru', 'mantle,(-dismantle)', 'lymsm', 'lymphoma']
#ash22 plenary session the triangle trial : the death knell for frontline asct in mantle cell lymphoma? - ibrutinib at least non inferior to asct (maybe better)
- ibr surprisingly well tolerated during induction
- 80% crossover to ibr in asct arm ( )
#lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer